Cargando…
CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protei...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562855/ https://www.ncbi.nlm.nih.gov/pubmed/28394345 http://dx.doi.org/10.1038/onc.2017.87 |
_version_ | 1783258023523778560 |
---|---|
author | Zoni, E Chen, L Karkampouna, S Granchi, Z Verhoef, E I La Manna, F Kelber, J Pelger, R C M Henry, M D Snaar-Jagalska, E van Leenders, G J L H Beimers, L Kloen, P Gray, P C van der Pluijm, G Kruithof-de Julio, M |
author_facet | Zoni, E Chen, L Karkampouna, S Granchi, Z Verhoef, E I La Manna, F Kelber, J Pelger, R C M Henry, M D Snaar-Jagalska, E van Leenders, G J L H Beimers, L Kloen, P Gray, P C van der Pluijm, G Kruithof-de Julio, M |
author_sort | Zoni, E |
collection | PubMed |
description | CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDH(high) sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDH(low). Coculture of the osteotropic PC-3M-Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and increases the size of the ALDH(high) sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration, clonogenicity and the size of the metastasis-initiating ALDH(high) sub-population. CRIPTO knockdown reduces the invasion of PC-3M-Pro4Luc2 cells in zebrafish and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have significant therapeutic potential. |
format | Online Article Text |
id | pubmed-5562855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55628552017-08-24 CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer Zoni, E Chen, L Karkampouna, S Granchi, Z Verhoef, E I La Manna, F Kelber, J Pelger, R C M Henry, M D Snaar-Jagalska, E van Leenders, G J L H Beimers, L Kloen, P Gray, P C van der Pluijm, G Kruithof-de Julio, M Oncogene Original Article CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDH(high) sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDH(low). Coculture of the osteotropic PC-3M-Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and increases the size of the ALDH(high) sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration, clonogenicity and the size of the metastasis-initiating ALDH(high) sub-population. CRIPTO knockdown reduces the invasion of PC-3M-Pro4Luc2 cells in zebrafish and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have significant therapeutic potential. Nature Publishing Group 2017-08-17 2017-04-10 /pmc/articles/PMC5562855/ /pubmed/28394345 http://dx.doi.org/10.1038/onc.2017.87 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Article Zoni, E Chen, L Karkampouna, S Granchi, Z Verhoef, E I La Manna, F Kelber, J Pelger, R C M Henry, M D Snaar-Jagalska, E van Leenders, G J L H Beimers, L Kloen, P Gray, P C van der Pluijm, G Kruithof-de Julio, M CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer |
title | CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer |
title_full | CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer |
title_fullStr | CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer |
title_full_unstemmed | CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer |
title_short | CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer |
title_sort | cripto and its signaling partner grp78 drive the metastatic phenotype in human osteotropic prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562855/ https://www.ncbi.nlm.nih.gov/pubmed/28394345 http://dx.doi.org/10.1038/onc.2017.87 |
work_keys_str_mv | AT zonie criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT chenl criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT karkampounas criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT granchiz criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT verhoefei criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT lamannaf criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT kelberj criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT pelgerrcm criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT henrymd criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT snaarjagalskae criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT vanleendersgjlh criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT beimersl criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT kloenp criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT graypc criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT vanderpluijmg criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer AT kruithofdejuliom criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer |